In summary, a targeted, personalized, precision medicine approach that addresses the multiple potential contributors to cognitive decline for each patient shows promise for the treatment of Alzheimer’s disease and its harbingers, MCI and SCI. The improvements documented in the 100 patients reported here provide support for the performance of a prospective, randomized, controlled clinical trial, especially given the current lack of effective treatment for this common and otherwise terminal illness.
Makes perfect sense and does not contradict/conflict w/Homeostasis thinking. One size does not fit all. Biomarkers matter. The dark period of Amyloid thesis if finally over.
Yes, some really fine therapeutic outcomes. Mental health of Alzheimer's patients wonderfully improved.
But, it was accomplished not with a drug but by an extremely detailed and complicated health "protocol." Simply, the therapists treated just a zillion health problems, and cognition improved.
Would (or could) you administer to Aunt Matilda all of the following when she started for forget stuff?
It seems to be a post hoc analysis. Only those who improved are included.
Proves nothing because we don't know if diagnosis was accurate to begin with.
"MCI, and early Alzheimer’s disease "
My knees hurt today, my cognition sucked.
If I get better tomorrow because my knees don't hurt and I take an asprin is the asprin a "cure" for my cognitive decline?
(Table 1) lists 100 patients with cognitive decline due to Alzheimer’s disease, pre-Alzheimer’s conditions MCI (Mild Cognitive Impairment) or SCI (Subjective Cognitive Impairment), or cognitive decline without definitive diagnosis, all of whom demonstrated documented improvement using the same targeted, multi-component program used for the three patients described above